Effective treatment of alpha-mannosidosis by allogeneic hematopoietic stem cell transplantation.
OBJECTIVE
To study the efficacy of hematopoietic stem cell transplantation (HCT) for ameliorating the clinical manifestations of alpha-mannosidosis.


METHODS
Four patients with alpha-mannosidosis underwent allogeneic HCT at the University of Minnesota. Diagnosis was established by assay of leukocyte alpha-mannosidase activity level. Physical features, donor engraftment, leukocyte alpha-mannosidase activity, neuropsychologic function, and hearing were monitored before and after transplantation, with follow-up ranging from 1 to 6 years.


RESULTS
All 4 patients showed slowing of their neurocognitive development and sensorineural hearing loss before HCT. All patients are alive, with normalization of leukocyte enzyme activity after HCT. Intellectual function has stabilized, with improvement in adaptive skills and verbal memory function in 3 of 4 patients. Hearing has improved to normal or near normal for speech frequencies in 3 patients. No new skeletal abnormalities have developed.


CONCLUSIONS
HCT can halt the progressive cognitive loss in patients with alpha-mannosidosis. Early diagnosis and treatment with HCT is critical for optimal results.
Grewal
Satkiran S
SS
Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA. grewa002@umn.edu
Shapiro
Elsa G
EG
Krivit
William
W
Charnas
Lawrence
L
Lockman
Lawrence A
LA
Delaney
Kathleen A
KA
Davies
Stella M
SM
Wenger
David A
DA
Rimell
Frank L
FL
Abel
Susan
S
Grovas
Alfred C
AC
Orchard
Paul J
PJ
Wagner
John E
JE
Peters
Charles
C
D000328:Adult; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D002658:Developmental Disabilities / Q000209:etiology / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D006319:Hearing Loss, Sensorineural / Q000209:etiology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008363:alpha-Mannosidosis / Q000150:complications / Q000628:therapy*